|
Dr. Ahlijanian has worked in Neuroscience for over 25 years with 15 years in CNS Discovery at Pfizer rising to the level of Executive Director. Ahlijanian has broad experience in small molecule drug discovery in both Neurodegenerative and Psychiatric diseases and has led or contributed to teams that have generated multiple compounds for clinical development. He also has significant experience in preclinical and clinical development. As VP of Research and Development, Michael is focused on the delivery of clinical candidates from Research and the preclinical development of these candidates prior to testing in human. Michael received his Ph.D. from the University of Minnesota (A. E. Takemori) and received post-doctoral training at the University of Colorado (D.M.F. Cooper) and the University of Washington (W.A. Catterall). He has published in key scientific and Neuroscience journals, is co-inventor on several issued US patents and has been an invited speaker to domestic and international meetings and symposia. | 